Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 12, 2011 - Issue 17
Submit an article Journal homepage
531
Views
13
CrossRef citations to date
0
Altmetric
Original Research

A cost-effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease

Kevin Lock Heron Evidence Development, Butterfield Technology and Business Park, Building 210A, Stopsley, Luton, LU2 8DL, UK+44 0 1582 433650; +44 0 1582 433651; [email protected]
,
Koo Wilson Pfizer Ltd, Walton Oaks, UK
,
Daniel Murphy Heron Evidence Development, Butterfield Technology and Business Park, Building 210A, Stopsley, Luton, LU2 8DL, UK+44 0 1582 433650; +44 0 1582 433651; [email protected]
, MSc &
Juan Antonio Riesco San Pedro de Alcantara Hospital, Cáceres, Spain
Pages 2613-2626 | Published online: 21 Oct 2011

Citations (13)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Thomas R. Einarson, Basil G. Bereza, T. Anders Nielsen & Michiel E. H. Hemels. (2015) Utilities for asthma and COPD according to category of severity: a comprehensive literature review. Journal of Medical Economics 18:7, pages 550-563.
Read now
Carlos A Jiménez-Ruiz, Segismundo Solano-Reina, Jaime Signes-Costa, Eva de Higes-Martinez, José I Granda-Orive, José J Lorza-Blasco, Juan A Riesco-Miranda, Neus Altet-Gomez, Miguel Barrueco, Itziar Oyagüez & Javier Rejas. (2015) Budgetary impact analysis on funding smoking-cessation drugs in patients with COPD in Spain. International Journal of Chronic Obstructive Pulmonary Disease 10, pages 2027-2036.
Read now
Florian Kirsch. (2015) A systematic review of quality and cost–effectiveness derived from Markov models evaluating smoking cessation interventions in patients with chronic obstructive pulmonary disease. Expert Review of Pharmacoeconomics & Outcomes Research 15:2, pages 301-316.
Read now

Articles from other publishers (10)

Charalampos Tzanetakos & George Gourzoulidis. (2023) Does a Standard Cost-Effectiveness Threshold Exist? The Case of Greece. Value in Health Regional Issues 36, pages 18-26.
Crossref
D. Thomas. (2019) Sevrage tabagique : un défi pour les cardiologues et les pneumologues. Revue des Maladies Respiratoires 36:4, pages 527-537.
Crossref
O. V. Zhukova, S. V. Kononova & T. M. Konyshkina. (2019) Statistical relationship between smoking and frequent exacerbations of chronic obstructive pulmonary disease. Profilakticheskaya meditsina 22:1, pages 79.
Crossref
J. Rejas-Gutiérrez, E. Bruguera & S. Cedillo. (2020) Modelling a budgetary impact analysis for funding drug-based smoking cessation therapies for patients with major depressive disorder in Spain. European Psychiatry 45, pages 41-49.
Crossref
Zafar Zafari, Stirling Bryan, Don D. Sin, Tania Conte, Rahman Khakban & Mohsen Sadatsafavi. (2017) A Systematic Review of Health Economics Simulation Models of Chronic Obstructive Pulmonary Disease. Value in Health 20:1, pages 152-162.
Crossref
Eva AM van Eerd, Regina M van der Meer, Onno CP van Schayck & Daniel Kotz. (2016) Smoking cessation for people with chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2019:3.
Crossref
Foruhar Moayeri, Ya-Seng (Arthur) Hsueh, Philip Clarke & David Dunt. (2016) Do Model-Based Studies in Chronic Obstructive Pulmonary Disease Measure Correct Values of Utility? A Meta-Analysis. Value in Health 19:4, pages 363-373.
Crossref
Shari P. Feirman, Elisabeth Donaldson, Allison M. Glasser, Jennifer L. Pearson, Ray Niaura, Shyanika W. Rose, David B. Abrams & Andrea C. Villanti. (2016) Mathematical Modeling in Tobacco Control Research: Initial Results From a Systematic Review. Nicotine & Tobacco Research 18:3, pages 229-242.
Crossref
David Gray. 2014. Drug Delivery to the Brain. Drug Delivery to the Brain 375 397 .
Douglas W. Mapel & Melissa H. Roberts. (2012) New Clinical Insights into Chronic Obstructive Pulmonary Disease and Their Implications for Pharmacoeconomic Analyses. PharmacoEconomics 30:10, pages 869-885.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.